Advanced Colloids Experiment (Temperature Controlled) - ACE-T2

Increment 57 - 58 Science Symposium presentation of Advanced Colloids Experiment (ACE-T2) to RPO. The purpose of this event is for Principal Investigators to present their science objectives, testing approach, and measurement methods to agency scientists, managers, and other investigators

Extreme mechanics of colloidal polymers under compression: Buckling, creep, and break-up

Self-assembling patchy colloidal particles form a promising platform to create designer soft materials. To dress such systems with mechanical functionality, one can take inspiration from biological structures such as the cell's cytoskeleton, which consists of semiflexible filaments, whose mechanical behavior give the cell its unique mechanical properties. Here we present mechanical experiments on analogs of biological fibers, semiflexible "colloidal polymers"made from bonded patchy colloidal particles. We use optical tweezers to probe their extreme mechanics under increasingly high compressions and we reveal a rich nonlinear mechanical response involving buckling, viscoelastic creep, and ultimately break-up. We characterize and model this response using elastic and viscoelastic models involving Euler buckling and stress relaxation. This allows us to identify the critical Euler buckling force, and relate the critical bending at break-up to the finite patch size of the colloids. These results demonstrate the crucial role of the patch-patch interactions in the mechanics of self-assembled colloidal materials, and they provide mechanical relationships that are essential to design functional colloidal architectures inspired by nature

Revealing viscoelastic bending relaxation dynamics of isolated semiflexible colloidal polymers

The viscoelastic properties of filaments and biopolymers play a crucial role in soft and biological materials from biopolymer networks to novel synthetic metamaterials. Colloidal particles with specific valency allow mimicking polymers and more complex molecular structures at the colloidal scale, offering direct observation of their internal degrees of freedom. Here, we elucidate the time-dependent viscoelastic response in the bending of isolated semi-flexible colloidal polymers, assembled from dipatch colloidal particles by reversible critical Casimir forces. By tuning the patch-patch interaction strength, we adjust the polymers' viscoelastic properties, and follow spontaneous bending modes and their relaxation directly on the particle level. We find that the elastic response is well described by that of a semiflexible rod with persistence length of order 1000 μm, tunable by the critical Casimir interaction strength. We identify the viscous relaxation on longer timescales to be due to internal friction, leading to a wavelength-independent relaxation time similar to single biopolymers, but in the colloidal case arising from the contact mechanics of the bonded patches. These tunable mechanical properties of assembled colloidal filaments open the door to “colloidal architectures”, rationally designed (network) structures with desired topology and mechanical properties

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events